Which play a more important role in the development of large-sized prostates (⇿0 ml), androgen receptors or oestrogen receptors? A comparative study

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Which play a more important role in the development of large-sized prostates (⇿0 ml), androgen receptors or oestrogen receptors? A comparative study

详细信息查看全文

作者：Peng Zhang ; Wan-Li Hu ; Bei Cheng ; Yang-Jun Zeng…
关键词：Androgen receptor ; Oestrogen receptor ; Benign prostatic hyperplasia ; Prostate volume
刊名：International Urology and Nephrology
出版年：2016
出版时间：March 2016
年：2016
卷：48
期：3
页码：325-333
全文大小：8,401 KB
参考文献：1.Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82(4–5):184–199. doi:10.1016/j.diff.2011.04.006 CrossRef PubMed PubMedCentral
2.Roehrborn CG (2011) Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin N Am 95(1):87–100. doi:10.1016/j.mcna.2010.08.013 CrossRef PubMed
3.Kaplan SA, He W, Koltun WD, Cummings J, Schneider T, Fakhoury A (2013) Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 63(1):158–165. doi:10.1016/j.eururo.2012.07.003 CrossRef PubMed
4.Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68(15):6407–6415. doi:10.1158/0008-5472.CAN-07-5997 CrossRef PubMed
5.Stone NN, Clejan SJ (1991) Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia. J Androl 12(6):376–380PubMed
6.McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185(5):1793–1803. doi:10.1016/j.juro.2011.01.074 CrossRef PubMed
7.Wei H, Shao Y, Sun F, Sun X, Zhuo J, Zhao F, Han B, Jiang J, Chen H, Xia S (2014) Thulium laser resection versus plasmakinetic resection of prostates larger than 80 ml. World J Urol 32(4):1077–1085. doi:10.1007/s00345-013-1210-4 CrossRef PubMed
8.Wen S, Chang HC, Tian J, Shang Z, Niu Y, Chang C (2015) Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. Am J Pathol 185(2):293–301. doi:10.1016/j.ajpath.2014.10.012 CrossRef PubMed PubMedCentral
9.Alonso-Magdalena P, Brossner C, Reiner A, Cheng G, Sugiyama N, Warner M, Gustafsson JA (2009) A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci USA 106(8):2859–2863. doi:10.1073/pnas.0812666106 CrossRef PubMed PubMedCentral
10.Garg M, Dalela D, Dalela D, Goel A, Kumar M, Gupta G, Sankhwar SN (2013) Selective estrogen receptor modulators for BPH: new factors on the ground. Prostate Cancer Prostatic Dis 16(3):226–232. doi:10.1038/pcan.2013.17 CrossRef PubMed
11.Krieg M, Nass R, Tunn S (1993) Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 77(2):375–381. doi:10.1210/jcem.77.2.7688377 PubMed
12.DeKlerk DP, Coffey DS, Ewing LL, McDermott IR, Reiner WG, Robinson CH, Scott WW, Strandberg JD, Talalay P, Walsh PC, Wheaton LG, Zirkin BR (1979) Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Investig 64(3):842–849. doi:10.1172/JCI109532 CrossRef PubMed PubMedCentral
13.Nicholson TM, Moses MA, Uchtmann KS, Keil KP, Bjorling DE, Vezina CM, Wood RW, Ricke WA (2015) Estrogen receptor-alpha is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia. J Urol 193(2):722–729. doi:10.1016/j.juro.2014.08.093 CrossRef PubMed PubMedCentral
14.Kawashima H, Nakatani T (2012) Involvement of estrogen receptors in prostatic diseases. Int J Urol 19(6):512–522. doi:10.1111/j.1442-2042.2012.02987.x (author reply 522–513) CrossRef PubMed
15.Liao CH, Li HY, Chung SD, Chiang HS, Yu HJ (2012) Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40–79 years. Aging Male 15(1):28–33. doi:10.3109/13685538.2010.550660 CrossRef PubMed
16.Schalken J, Fitzpatrick JM (2015) Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int. doi:10.1111/bju.13123 PubMed PubMedCentral
17.Roehrborn CG, Spann ME, Myers SL, Serviss CR, Hu L, Jin Y (2015) Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. Prostate Cancer Prostatic Dis 18(1):43–48. doi:10.1038/pcan.2014.43 CrossRef PubMed
18.Joseph MA, Wei JT, Harlow SD, Cooney KA, Dunn RL, Jaffe CA, Montie JE, Schottenfeld D (2002) Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate 53(4):322–329. doi:10.1002/pros.10154 CrossRef PubMed
19.Zeng QS, Xu CL, Liu ZY, Wang HQ, Yang B, Xu WD, Jin TL, Wu CY, Huang G, Li Z, Wang B, Sun YH (2012) Relationship between serum sex hormones levels and degree of benign prostate hyperplasia in Chinese aging men. Asian J Androl 14(5):773–777. doi:10.1038/aja.2012.32 CrossRef PubMed PubMedCentral
20.Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I (2002) Estradiol in elderly men. Aging Male 5(2):98–102CrossRef PubMed
21.Coffey DS, Walsh PC (1990) Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin N Am 17(3):461–475
22.Carson C 3rd, Rittmaster R (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61(4 Suppl 1):2–7CrossRef PubMed
23.Pelletier G (2008) Expression of steroidogenic enzymes and sex-steroid receptors in human prostate. Best Pract Res Clin Endocrinol Metab 22(2):223–228. doi:10.1016/j.beem.2008.02.004 CrossRef PubMed
24.Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA (1997) Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82(12):4258–4265. doi:10.1210/jcem.82.12.4470 PubMed
25.Sugiyama N, Barros RP, Warner M, Gustafsson JA (2010) ERbeta: recent understanding of estrogen signaling. Trends Endocrinol Metab: TEM 21(9):545–552. doi:10.1016/j.tem.2010.05.001 CrossRef PubMed
26.McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang Y, Taylor RA, Risbridger GP (2010) Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA 107(7):3123–3128. doi:10.1073/pnas.0905524107 CrossRef PubMed PubMedCentral
27.Nomura H, Kawashima H, Masaki S, Hosono TY, Matsumura K, Tamada S et al (2009) Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells. Prostate Cancer Prostatic Dis 12(4):375–381. doi:10.1038/pcan.2009.20 CrossRef PubMed
28.Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D et al (2010) Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 184(4):1316–1321. doi:10.1016/j.juro.2010.06.022 CrossRef PubMed PubMedCentral
29.Taneja SS, Morton R, Barnette G, Sieber P, Hancock ML, Steiner M (2013) Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol 31(5):523–529. doi:10.1200/JCO.2012.41.7634 CrossRef PubMed
30.Yatkin E, Bernoulli J, Talvitie EM, Santti R (2009) Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio. Int J Androl 32(4):399–410. doi:10.1111/j.1365-2605.2008.00930.x CrossRef PubMed
31.Nicholson TM, Sehgal PD, Drew SA, Huang W, Ricke WA (2013) Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment. Differentiation 85(4–5):140–149. doi:10.1016/j.diff.2013.02.006 CrossRef PubMed PubMedCentral
作者单位：Peng Zhang (1)
Wan-Li Hu (1)
Bei Cheng (2)
Yang-Jun Zeng (1)
Xing-Huan Wang (1)
Tong-Zu Liu (1)
Wei-Bing Zhang (1)

1. Department of Urology, Zhongnan Hospital, Wuhan University, 169 Donghu Road, Wuchang District, Wuhan, 430071, Hubei, People’s Republic of China
2. Department of Anatomy and Embryology, Wuhan University School of Basic Medical Sciences, Wuhan University, Wuhan, 430071, Hubei, People’s Republic of China
刊物类别：Medicine
刊物主题：Medicine & Public Health
Nephrology
Urology and Andrology
出版者：Springer Netherlands
ISSN：1573-2584

文摘

Objective To compare the expression levels of androgen receptor (AR), oestrogen receptor α (ERα)and oestrogen receptor β (ERβ) in human prostate with various degrees of benign hyperplasia.